GC
VOR icon

Grimes & Company’s Vor Biopharma VOR Stock Holding History

Grimes & Company’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-757
Closed -$10.6K – 399
2024
Q3 		$10.6K Hold
757
– – ﹤0.01% 366
2024
Q2 		$15.1K Buy
757
+51
+7% +$1.65K ﹤0.01% 347
2024
Q1 		$33.5K Buy
706
+23
+3% +$1.01K ﹤0.01% 339
2023
Q4 		$30.7K Sell
683
-16
-2% -$660 ﹤0.01% 326
2023
Q3 		$29.6K Buy
699
+18
+3% +$976 ﹤0.01% 296
2023
Q2 		$42.1K Hold
681
– – ﹤0.01% 302
2023
Q1 		$73.3K Buy
681
+138
+25% +$15.3K ﹤0.01% 288
2022
Q4 		$72.2K Buy
+543
New +$53.7K ﹤0.01% 280

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Grimes & Company's VOR Position: Q4 2024 in Review

Grimes & Company sold out of Vor Biopharma (VOR) in Q4 2024, closing a stake of 757 shares — an estimated $10.6K sold.

Grimes & Company first reported a position in VOR in Q4 2022 and held it in 8 quarters. The position peaked at $73.3K in Q1 2023. 50 funds tracked by Wall St. Rank hold VOR as of Q4 2024.

  • Grimes & Company reported no remaining Vor Biopharma position as of Q4 2024 after selling out during the quarter.
  • Grimes & Company sold 757 Vor Biopharma shares in Q4 2024, an estimated $10.6K.
  • Grimes & Company first reported a position in Vor Biopharma in Q4 2022 and held it in 8 quarters.
  • Grimes & Company's Vor Biopharma position peaked at $73.3K in Q1 2023.
  • 50 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2024.

Based on Grimes & Company's 13F filing for Q4 2024, filed 21 Jan 2025.